Octreotide acetate CR is under clinical development by ASCIL Biopharm and currently in Phase I for Acromegaly. According to GlobalData, Phase I drugs for Acromegaly have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Octreotide acetate CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Octreotide acetate CR overview

Octreotide is under development for the treatment of neuroendocrine tumors (NET) and acromegaly. It is a controlled release formulation administered through subcutaneous and intramuscular route. The drug candidate acts by targeting somatostatin receptor (SSTR2 and SSRT5).

ASCIL Biopharm overview

ASCIL Biopharm (Ascil) operates as a developer of patented injectable and commercial controlled-release therapeutics. The company develops advanced drug delivery system formulations and medical devices for the administration of drugs for chronic diseases. Its pipeline includes formulations for quarterly administration of high-dose biologics and immediate release ready-to-use drug delivery system of emergency drugs and peptides for chronic disease. Ascil conducts research and development programs to achieve product performance for safety issues related to intravitreal long-acting products and dermo-cosmetic targeted delivery technologies for skin health improvements. The company offers its solutions in the field of pharma, biotech, aesthetic and veterinary care. Ascil is headquartered in Viladecans, Spain.

For a complete picture of Octreotide acetate CR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.